CDEK
← All drugs Report issue

basmisanil

Small moleculeexperimental

Basmisanil is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of June 2016, it is no longer studied for this purpose. It underwent a clinical trial for cognitive impairment in patients with schizophrenia. — Wikipedia

Clinical trial activity

13 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2011 (NCT01436955)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1onc(-c2ccc(F)cc2)c1COc1ccc(C(=O)N2CCS(=O)(=O)CC2)cn1
Mol. weight
445.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • basmisanil
  • basmisanil
  • basmisanil
  • basmisanil
  • rg1662
  • rg1662
  • rg-1662
  • rg-1662
  • ro5186582

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05307679Phase 2Dec 16, 2022Roche
NCT02928393Phase 2Feb 20, 2017Roche
NCT02953639Phase 2Nov 30, 2016Roche
NCT02484703Phase 2Oct 28, 2015Roche
NCT02534207Phase 1Aug 1, 2015Roche
NCT02470832Phase 1May 1, 2015Roche
NCT02342925Phase 1Feb 1, 2015Roche
NCT02254759Phase 1Oct 1, 2014Roche
NCT02194244Phase 1Aug 1, 2014Roche
NCT02024789Phase 2May 1, 2014Roche
NCT01684891Phase 1Sep 1, 2012Roche
NCT01667367Phase 1Aug 1, 2012Roche
NCT01436955Phase 1Nov 1, 2011Roche
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RocheFor profit131322011
1 organizations
Page 1 / 1